pre-update Archives

Blog

How has the Inflation Reduction Act Impacted the Biosimilars Market?

The Inflation Reduction Act (IRA), one of the key legislative achievements the Biden-Harris administration, aims…

CertaraAugust 27, 2024

Fact Sheet

Phoenix™ NLME

CertaraAugust 26, 2024

Fact Sheet

Phoenix™ PK/PD Platform Overview

CertaraAugust 26, 2024

Press Coverage

FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

CertaraAugust 26, 2024

Publication

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…

CertaraAugust 26, 2024

Publication

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…

CertaraAugust 26, 2024

Press Coverage

The Uncertain Path Forward for Psychedelic Medicine

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

CertaraAugust 26, 2024

Blog

Streamline your clinical trials with automated metadata management

When it comes to efficient clinical study build, content is king. Most importantly: metadata content.…

CertaraAugust 26, 2024

Blog

Regulatory requirements for annotated CRFs made easy

aCRFs are a mandatory requirement of the FDA, and therefore a key submission deliverable for…

CertaraAugust 26, 2024

Blog

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…

CertaraAugust 23, 2024

pre-update

How has the Inflation Reduction Act Impacted the Biosimilars Market?

Phoenix™ NLME

Phoenix™ PK/PD Platform Overview

FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The Uncertain Path Forward for Psychedelic Medicine

Streamline your clinical trials with automated metadata management

Regulatory requirements for annotated CRFs made easy

Resmetirom: A pioneering NASH clinical program

Newsletter sign up

Quick links

Solutions

Contact